Literature DB >> 16927176

Significance of interleukin-6 (IL-6) in breast cancer (review).

Heike Knüpfer1, Rainer Preiss.   

Abstract

Cytokines are factors that are known to have both tumor-promoting and inhibitory effects on breast cancer growth depending presumably on their relative concentrations and the presence of other modulating factors. Different cytokines play an important role in controlling the immune system. Interleukin-6 (IL-6) is a pleiotropic cytokine with obviously tumor-promoting and tumor-inhibitory effects. Here, we review the role of IL-6 in in vitro experiments of breast tumor cells, in breast tumor tissues (BTs) and assess its potential as a prognostic indicator in breast cancer patients. A literature search was conducted using PubMed, restricted to articles published in English language. In summary, results regarding the effect of IL-6 on breast tumor cells and on BTs are not unique indicating both tumor-promoting and inhibitory effects of IL-6. Concerning patients' serum IL-6 levels, data are surprisingly unique showing IL-6 to be a negative prognosticator in breast tumor patients.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16927176     DOI: 10.1007/s10549-006-9328-3

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  172 in total

1.  The JAK2/STAT3 signaling pathway is required for growth of CD44⁺CD24⁻ stem cell-like breast cancer cells in human tumors.

Authors:  Lauren L C Marotta; Vanessa Almendro; Andriy Marusyk; Michail Shipitsin; Janina Schemme; Sarah R Walker; Noga Bloushtain-Qimron; Jessica J Kim; Sibgat A Choudhury; Reo Maruyama; Zhenhua Wu; Mithat Gönen; Laura A Mulvey; Marina O Bessarabova; Sung Jin Huh; Serena J Silver; So Young Kim; So Yeon Park; Hee Eun Lee; Karen S Anderson; Andrea L Richardson; Tatiana Nikolskaya; Yuri Nikolsky; X Shirley Liu; David E Root; William C Hahn; David A Frank; Kornelia Polyak
Journal:  J Clin Invest       Date:  2011-07       Impact factor: 14.808

2.  Signal transducers and activators of transcription 3 (STAT3) directly regulates cytokine-induced fascin expression and is required for breast cancer cell migration.

Authors:  Marylynn Snyder; Xin-Yun Huang; J Jillian Zhang
Journal:  J Biol Chem       Date:  2011-09-20       Impact factor: 5.157

3.  Fatigue and sleep quality are associated with changes in inflammatory markers in breast cancer patients undergoing chemotherapy.

Authors:  Lianqi Liu; Paul J Mills; Michelle Rissling; Lavinia Fiorentino; Loki Natarajan; Joel E Dimsdale; Georgia Robins Sadler; Barbara A Parker; Sonia Ancoli-Israel
Journal:  Brain Behav Immun       Date:  2012-03-02       Impact factor: 7.217

4.  HER2 overexpression elicits a proinflammatory IL-6 autocrine signaling loop that is critical for tumorigenesis.

Authors:  Zachary C Hartman; Xiao-Yi Yang; Oliver Glass; Gangjun Lei; Takuya Osada; Sandeep S Dave; Michael A Morse; Timothy M Clay; Herbert K Lyerly
Journal:  Cancer Res       Date:  2011-04-25       Impact factor: 12.701

Review 5.  Minireview: Inflammation: an instigator of more aggressive estrogen receptor (ER) positive breast cancers.

Authors:  Sarah C Baumgarten; Jonna Frasor
Journal:  Mol Endocrinol       Date:  2012-02-02

6.  Activation of Toll-like receptor 5 on breast cancer cells by flagellin suppresses cell proliferation and tumor growth.

Authors:  Zhenyu Cai; Amir Sanchez; Zhongcheng Shi; Tingting Zhang; Mingyao Liu; Dekai Zhang
Journal:  Cancer Res       Date:  2011-03-22       Impact factor: 12.701

7.  Elevated serum levels of sialyl Lewis X (sLeX) and inflammatory mediators in patients with breast cancer.

Authors:  Evan N Cohen; Tamer M Fouad; Bang-Ning Lee; Banu K Arun; Diane Liu; Sanda Tin; Angelica M Gutierrez Barrera; Toshihide Miura; Iwao Kiyokawa; Jun Yamashita; Ricardo H Alvarez; Vicente Valero; Wendy A Woodward; Yu Shen; Naoto T Ueno; Massimo Cristofanilli; James M Reuben
Journal:  Breast Cancer Res Treat       Date:  2019-05-03       Impact factor: 4.872

Review 8.  Emerging evidence for the role of differential tumor microenvironment in breast cancer racial disparity: a closer look at the surroundings.

Authors:  Sachin Kumar Deshmukh; Sanjeev K Srivastava; Nikhil Tyagi; Aamir Ahmad; Ajay P Singh; Ahmed A L Ghadhban; Donna L Dyess; James E Carter; Kari Dugger; Seema Singh
Journal:  Carcinogenesis       Date:  2017-08-01       Impact factor: 4.944

9.  Obesity promotes resistance to anti-VEGF therapy in breast cancer by up-regulating IL-6 and potentially FGF-2.

Authors:  Joao Incio; Jennifer A Ligibel; Daniel T McManus; Priya Suboj; Keehoon Jung; Kosuke Kawaguchi; Matthias Pinter; Suboj Babykutty; Shan M Chin; Trupti D Vardam; Yuhui Huang; Nuh N Rahbari; Sylvie Roberge; Dannie Wang; Igor L Gomes-Santos; Stefan B Puchner; Christopher L Schlett; Udo Hoffmman; Marek Ancukiewicz; Sara M Tolaney; Ian E Krop; Dan G Duda; Yves Boucher; Dai Fukumura; Rakesh K Jain
Journal:  Sci Transl Med       Date:  2018-03-14       Impact factor: 17.956

Review 10.  The immune system in the pathogenesis of ovarian cancer.

Authors:  Bridget Charbonneau; Ellen L Goode; Kimberly R Kalli; Keith L Knutson; Melissa S Derycke
Journal:  Crit Rev Immunol       Date:  2013       Impact factor: 2.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.